drugset / Trial / NCT05028140

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

NCT05028140

Phase 3 Recruiting 480 enrolled EMS
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus

Timeline

Start
2024-10-08
Primary completion
2026-07
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Empagliflozin Small molecule 25 mg Oral
Subject Piemonte association Unknown Oral
Comparator Pioglitazone Small molecule 30 mg Oral